MZ Badania Slowik Zymla Sp.j.

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis9 trials
• Crohn's disease4 trials
• Coeliac disease1 trial

Phase

• Phase 37 trials
• Phase 26 trials
• Phase 11 trial

Status

• Completed8 trials
• Active, not recruiting3 trials
• Recruiting3 trials

Lead sponsor

• Abivax S.A.3 trials
• Hoffmann-La Roche2 trials
• Alvotech Swiss AG1 trial
• Anaptysbio Inc.1 trial
• Boehringer Ingelheim International GmbH1 trial
• and 6 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Abivax S.A.· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT05197049· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

  NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.

  NCT05549323· Phase 1· Pfizer Inc.· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease

  NCT04978493· Phase 2· Boehringer Ingelheim International GmbH· Source